Quoin Pharmaceuticals Ltd... (QNRX)
| Bid | 5.01 |
| Market Cap | 3.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.98M |
| EPS (ttm) | -66.85 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -13.7 |
| Analyst | Buy |
| Ask | 6.8 |
| Volume | 31,547 |
| Avg. Volume (20D) | 259,533 |
| Open | 6.17 |
| Previous Close | 6.00 |
| Day's Range | 5.46 - 6.51 |
| 52-Week Range | 5.01 - 54.95 |
| Beta | 1.61 |
About QNRX
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia....
Analyst Forecast
According to 1 analyst ratings, the average rating for QNRX stock is "Buy." The 12-month stock price forecast is $4, which is a decrease of -26.99% from the latest price.
Stock Forecasts
2 months ago · accessnewswire.com
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesLAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and...